BGPartner advises OrbiMed and Novo on $181.4m financing
Swiss biotech company Alentis Therapeutics has successfully closed a $181.4 million oversubscribed Series D financing round, supported by a syndicate of top-tier biotech investors. The financing will support the company to develop a deep pipeline of CLDN1 targeted medicines for solid tumors.
The funding round was led by OrbiMed with co-leads Novo Holdings and Jeito Capital. New investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital and Avego Bioscience Capital participated in the round. Significant backing was also received from existing investor RA Capital Management, along with support from Morningside Venture Investments, BB Pureos, Bpifrance through its InnoBio 2 fund.
BGPartner advised lead investors OrbiMed and Novo Holdings on all Swiss legal matters and the negotiations of this Series D financing round. The team consisted of partner Oliver Gnehm (pictured), Victoria Marty (Senior Associate) and Tessa Douma (Associate).
From the other side, Alentis Therapeutics was advised by Walder Wyss.
